Patents by Inventor Antonio Pellicer

Antonio Pellicer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stem cell therapy in endometrial pathologies
    Patent number: 11129851
    Abstract: The invention generally relates to the ability of autologous CD133+ bone marrow stem cells (BMDSC) to induce endometrial regeneration and treat endometrial pathologies such as Asherman's syndrome and endometrial atrophy. Methods to induce endometrial regeneration are provided, which comprises administering an effective amount of autologous CD133+ bone marrow derived stem cells (BMDSC) into uterine arteries of a subject in need thereof to induce endometrial regeneration.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: September 28, 2021
    Assignee: IGENOMIX S.L.
    Inventors: Carlos Simón, Xavier Santamaria, Irene Cervelló, Antonio Pellicer
  • STEM CELL THERAPY IN ENDOMETRIAL PATHOLOGIES
    Publication number: 20170128492
    Abstract: The invention generally relates to the ability of autologous CD133+ bone marrow stem cells (BMDSC) to induce endometrial regeneration and treat endometrial pathologies such as Asherman's syndrome and endometrial atrophy. Methods to induce endometrial regeneration are provided, which comprises administering an effective amount of autologous CD133+ bone marrow derived stem cells (BMDSC) into uterine arteries of a subject in need thereof to induce endometrial regeneration.
    Type: Application
    Filed: June 5, 2015
    Publication date: May 11, 2017
    Applicant: Igenomix S.L.
    Inventors: Carlos Simón, Xavier Santamaria, Irene Cervelló, Antonio Pellicer
  • EARLY DETECTION OF PREECLAMPSIA
    Publication number: 20170097358
    Abstract: The invention provides non-invasive assays to reliably identify women who have or are predisposed to developing preeclampsia (PE). The method comprises measuring a level of annexin A2 (ANXA2) in a test sample obtained of a subject; and identifying the subject as having preeclampsia or at an increased risk of developing preeclampsia when the level of ANXA2 in the test sample is decreased in relation to a control sample. Methods to treat subject identified as having PE or at an increased risk of developing preeclampsia are also provided.
    Type: Application
    Filed: March 19, 2015
    Publication date: April 6, 2017
    Applicant: Igenomix S.L.
    Inventors: Carlos Simón, Tamara Garrido, Antonio Pellicer